International Clinical and Medical Case Reports Journal (ISSN: 2832-5788) | Volume 3, Issue 10 | Opinion Article | Open Access DOI
Nemat Khansari*
Tehran University of Medical Sciences, School of Medicine, Department of Immunology, Tehran, Iran
*Correspondence to: Nemat Khansari
Fulltext PDFThe development of personalized cancer immunotherapies represents a significant advancement in cancer treatment, aiming to tailor treatments based on the unique genetic makeup of individual tumors. Tumor-specific antigens (TSAs) are not expressed in normal cells. TSAs are suitable choices for cancer immunotherapy and cancer vaccines. Tumor cells harbor mutations in genes controlling cell growth and other genes. Mutation in genes that prevent the repairs of deoxyribonucleic acids (DNA) errors in cell division so, so-called mismatch repairs, have the potential to express neoantigens on the surface of the tumor cells and be used for personalized cancer immunotherapy [1]. Based on our experiences and available data, neoantigen-based vaccines represent a potential new class of cancer immunotherapy [2].
Nemat Khansari. Challenges and Limitations of Personalized Cancer Immunotherapies. Int Clinc Med Case Rep Jour. 2024;3(10):1-3.